Skip to main content
. 2012 Jul 17;2012:985620. doi: 10.1155/2012/985620

Figure 4.

Figure 4

ER−: odds ratios for developing an estrogen receptor-negative invasive breast cancer among women involved in tamoxifen prevention trials.